Breast and prostate cancers are among the most prevalent cancers worldwide. Oestradiol and progesterone are major drivers for breast cancer proliferation, and androgens for prostate cancer. Endocrine therapies are drugs that interfere with hormone-activated pathways to slow cancer progression. Multiple new breakthrough drugs improving overall survival have recently been developed within this class. As the use of these latter drugs grows, incidence of cardiac arrhythmias has emerged as an unappreciated complication. These changes are not surprising given that sex hormones alter ventricular repolarization. Testosterone shortens action potential duration and QT interval duration, while oestradiol has an opposite effect. In patients with breast cancer, selective oestrogen receptor modulators are associated with more reports for long QT and torsade de pointes (TdP) than aromatase inhibitors, likely through an oestradiol-like effect on the heart. Cyclin-dependent kinase 4/6 inhibitors, a new class of anticancer drugs used in combination with endocrine therapies in hormone receptor positive breast cancer, are also variably associated with drug-induced long QT, particularly with ribociclib. In prostate cancer, androgen deprivation therapy is associated with long QT and TdP, and possibly atrial fibrillation for abiraterone. In this review, we have summarized the clinical and preclinical data focusing on cardiac arrhythmia considerations of hormone cancer therapies.
Introduction
The most frequently diagnosed cancers in the United States are hormone-sensitive cancers, or cancers mediated by abnormalities in hormone production or hormone-receptor expression. 1 These cancers manifest in organs sensitive to sex hormones such as the breast, endometrium, and prostate (30%, 7%, and 19% of all cancer diagnoses, respectively). 1 Generally, breast and prostate cancers have some of the highest 5-year survival rates (90% and 99% survival, respectively) and require prolonged treatments. 1 Cancer is more likely to occur in these tissues when sex hormones, such as testosterone and oestrogen, act as potent growth factors that stimulate unregulated cell growth and tumourigenesis. Once the hormone engages its receptor, a cascade of events is necessary for transcriptional activation including conformational changes, hormone-dependent phosphorylation, receptor dimerization, and interaction with coregulatory molecules. [2] [3] [4] [5] The hormone-receptor complex may then bind to promoter regions to activate gene-regulated pathways, such as the oestrogen-mediated activation of lipocalin-type prostaglandin D synthase in the heart. 6 Alternatively, sex hormones are capable of activating cytoplasm and membrane-bound receptors, some that promote cellular growth and division such as the oncogenic mitogen-activating protein kinase (MAPK) cascade. 6, 7 The multifactorial involvement of hormones in tumourigenesis has prompted development of so-called endocrine therapies. These are drugs that interfere with hormone-activated pathways to slow cancer progression ( Table 1 and Figures 1 and 2) . Interestingly, as use of hormone-mediated therapies grows and the data expand, an unappreciated incidence of cardiac arrhythmia occurs in some patients. 8, 9 Specifically, electrophysiological changes including atrial fibrillation (AF), QT prolongation (LQT), and torsade de pointes (TdP) have been reported in the setting of cancer treatment using exogenous hormonal drugs. 8, [10] [11] [12] These changes are somewhat unsurprising given that endogenous and exogenous sex hormones have distinct effects on ventricular repolarization. 13 Testosterone in men and progesterone in women have QTc shortening effects, whereas oestradiol in women prolongs QTc. 13, 14 In healthy non-menopausal women, drospirenone, an anti-androgenic pill, was associated with increased sotalol-induced QTc prolongation (þ6-7 ms) as compared to no pill or levonorgestrel (highly androgenic). 15, 16 Therefore, altering sex hormone receptors pathways through endocrine therapies, may modify ventricular repolarization and be associated with proarrhythmia. The QT interval, corrected for heart rate (QTc), 17, 18 when prolonged, is a predictor for a specific ventricular arrhythmia called TdP. 19, 20 Many pharmaceutical agents prolong QTc by interacting with cardiac ion channels, mainly blocking the potassium channel I Kr (delayed rectifier potassium current) and, as more recently described, enhancing the late sodium current (I NaL ). 21 This has been shown for prolongation of ventricular repolarization with several oncologic drugs, notably mediated by inhibition of the a-subunit of phosphoinositide 3-kinase. 22, 23 Multidisciplinary approaches have been used to assess LQT during preclinical as well as in clinical development of each new therapy developed as part of so called thorough QT studies. 24 Most of these data are available on the FDA website (Drugs@FDA) and on CredibleMeds website. 25, 26 CredibleMeds is an online database of drugs known to prolong QT interval and induce TdP, directly or indirectly. Each drug is ranked as having either a conditional, a possible, or a known risk for TdP or to be avoided in Congenital LQT Syndromes (cLQTS). 25 The severity of arrhythmia risk for hormone therapies is cancer and drug-specific and dependent on the drug mechanism of action. New findings have caused this field within Cardio-Oncology to evolve rapidly, especially in light of new findings on arrhythmias associated with endocrine therapies used for cancer patients. 8, 9, 11, [27] [28] [29] Here, we summarize the clinical and preclinical data concerning cardiac arrhythmia considerations of therapies of hormone-sensitive cancers, i.e. mainly breast and prostate cancer patients.
Hormone therapies for breast cancer
Breast cancer therapies for hormone-sensitive cancers include a range of targets that reduce circulating oestrogen in the body or that antagonize Figure 1 Breast cancer hormone therapies reduce circulating oestrogen or inhibit oestrogen downstream activation pathways through various targets.
Aromatase inhibitors (AIs) are classically used in post-menopausal women. Selective oestrogen receptor modulators (SERMs) and degraders (SERDs) work at the receptor level to block activation of oestrogen receptor and to prevent nuclear translocation and/or transcription. Cyclin-dependent kinase (CDK) 4/6 inhibitors block the activation of the cyclin D/CDK 4/6 pathway and initiates cell cycle arrest through blockade at the S phase of the cell cycle. Red signs in boxes represent the different anticancer drugs classified by mechanisms of action. progesterone-receptor (PR) nuclear expression by immunohistochemistry is a standard for each new diagnosis of breast cancer. Hormonereceptor expression is both a good prognosis factor and a predictive factor of tumour response to endocrine therapies. 30 Another important receptor that may be expressed on the breast cancer cell is the human epidermal growth factor receptor 2 (HER2). HER2 directed therapies, (i.e. trastuzumab, pertuzumab, trastuzumab emtansine, lapatinib) may be associated with cardiovascular complications, mainly hypertension and heart failure, but they are not typically associated with cardiac arrhythmias. However, a subset of so-called hormone therapies for breast cancer have FDA warnings for LQT and TdP. 26 Hormone treatments act by antagonizing the ER or by inhibiting oestrogen biosynthesis as shown in Table 1 and Figure 1 . 9, 30 Currently, first-line therapies for ER þ breast cancer in pre-and post-menopausal women include selective oestrogen receptor modulators (SERMs), selective oestrogen receptor degraders (SERDs), aromatase inhibitors (AIs), and the newest addition of cyclindependent kinase (CDK) 4/6 inhibitors. 28, 31, 32 Growing data suggest that hormone therapies in breast cancer treatment may be associated with distinct cardiovascular and arrhythmogenic risk factors.
Selective oestrogen receptor modulators
The most prominent risk for LQT and TdP occurs with SERMs, or drugs that modify ER signalling. 9 Tamoxifen and toremifene are approved
SERMs that have variable antagonistic/agonistic activity in different tissues. In the breast, SERMs are antagonistic to the ER, blocking the natural oestrogenic response, while they are generally considered to have agonistic properties in the cardiovascular system. 9, 33 Tamoxifen, works in ER þ patients with breast cancer by binding with high affinity to the ER.
Tamoxifen contains a bulky side chain that causes the ER to undergo a conformational change that recruits corepressors, leading to 34 Tamoxifen, though highly efficacious, is associated with adverse agonistic effects on the uterine lining and has a black box warning for uterine malignancies in the FDA label. 26 Risks of uterine malignancies with tamoxifen led to the development of second-generation SERMs such as toremifene. Toremifene has similar anti-cancer activity to tamoxifen; however, this second-generation drug was found to prolong QTc in a dose-and concentration-related manner (from þ7 ms to þ65 ms for a 20 mg to 300 mg administration) in a thorough QT study, leading the FDA to issue a black boxed warning for LQT and TdP risk for toremifene. 26, 35 The pharmacological similarity between tamoxifen and toremifene (one chloride atom difference) suggests that they influence ventricular repolarization through a similar mechanism of action. Safety comparisons between tamoxifen and toremifene have not been made with respect to QTc and TdP because Tamoxifen (standard dose: 20 mg/day) was approved before the systematic requirement for dedicated thorough QT studies, leading to no particular warning in its FDA label. Two Phase I trials investigating the use of high-dose tamoxifen (80-680 mg/m 2 /day) in paediatric malignant gliomas (n = 14) and advanced epithelial tumours (n = 53) have shown that up to 40% of patients had a LQT > _10% and one-tenth had a marked QTc increase with prolongation > _20%. 36, 37 In these trials, one patient had premature ventricular contractions and LQT associated with sudden death. 36, 37 Overall, ventricular arrhythmias and TdP induced by SERMs have rarely been reported in the literature despite the fact that SERMs have been widely used for breast cancer patients. A previous literature review found 21 cases of ventricular arrhythmias or TdP in patients treated with SERMs for cancer. 9 Taken together, these data support that electrocardiographic monitoring might be considered in patients on SERMs, particularly when at risk of TdP.
The association of SERMs and TdP is related to QTc interval prolongation. Mechanisms include inhibition of the rapidly activating delayed rectifier potassium channel (I Kr ), a mechanism also involved in oestradiol-induced LQT. 13, 20 Pre-clinical models showed the role of tamoxifen and its active metabolite, endoxifen, on ventricular repolarization at clinically relevant concentrations. [38] [39] [40] [41] [42] Indeed, in human embryonic kidney cells, tamoxifen, and endoxifen inhibited I Kr currents by modifying concentration-dependent transmembrane transport and by direct channel blockade. 13, 40 This I Kr blockade was also evidenced in Xenopus laevis oocytes in which pathways identified were (i) adenylate cyclase and protein kinase A pathway and (ii) the bi-directional phospholipase C-diacylglycerol-protein kinase C and phospholipase C-1, 4,5-triphosphate-Ca 2þ pathway. 41 Counterbalancing the I Kr current inhibition, SERMs were also associated with a multi-channel blockade of sodium (rat cardiomyocytes) and L-type calcium (rabbit and canine cardiomyocytes) currents, which limit QTc increase and result in a modest ventricular repolarization prolongation. 38, 39, 42 Because I Kr inhibition has also been related to variations of endogenous sex hormones, 13 the combined influence of SERMs, gender, hormones, and ventricular ion channels on QTc increase remains to be fully understood in the scope of human pathophysiology. Of note, several studies in post-menopausal women (with significant reductions in oestrogen concentration) assessed the effects of hormone-replacement therapy on the QTc interval. They indicated that replacement with oestrogen alone, and not with the counter-balancing hormone progestin, caused lengthening of the QTc interval. [43] [44] [45] [46] [47] Altogether, these data support the mechanism of arrhythmia caused by SERMs through off-target signalling by mimicking the QTc prolonging effects of oestrogen, at least in part ( Figure 3 ).
Selective oestrogen receptor degraders
Other therapies that interfere with ER signalling are SERDs. These molecules bind to the ER and prevent dimerization, nuclear translocation, and DNA binding in cancer cells. 28, 34 SERDs were initially developed as a Figure 3 SERMs and ADT have specific effects on ventricular repolarization through modification of ion channels. SERMs are thought to prolong the QTc interval by mimicking oestrogen on cardiomyocytes and interacting with I K1 , I CaL , I Ks , and I Kr . ADT has opposite effects on ventricular repolarization of testosterone, causing a lengthening of the interval through modification of the ion channels I CaL , I Ks , and I Kr .
Cancer endocrine therapies and arrhythmias
Table 2
Results of preclinical studies evaluating influence of androgens (testosterone, T; 5a-dihydrotestosterone, and DHT) and androgen deprivation therapy on ventricular repolarization
Type of experiments and models used
Major results
Human derived cells 
Table 2 Continued
Major results • Castrated male rats administered T and studied in vivo for up to 2 weeks.
Rats
• ECG recordings, patch-clamp techniques western blotting, and mRNA expression by real-time PCR (Kv7.1, minK, Kv11.1, MiRP1, Kv4.2, Kv4.3, KChIP2, Kir2.1, and SP1)
• T shortened QT in ECG in castrated males, after 2 days and up to 2 weeks (not before).
• Kv7.1 (IKs) expression up-regulated by chronic (but not acute) DHT in rats cardiomyocytes through transcription factor SP1. Other K þ channel expression unchanged. 
Guinea pigs

Table 2 Continued
Major results
Rabbits
78-85
• Male (n = 4) and female rabbits controls (n = 4) or ovariectomized at 5 months (OVX, n = 16)
78
• ECG recordings evaluating effects on QTc at baseline and after quinidine of OVX plus vehicle (n = 4) or plus hormones (either DHT or oestradiol for 20 days, n = 6 each)
• • APD 30 shorter in control male vs. female and in castrated male vs. OVX
• Chromanol 293B had no effect on APD 90 in males or females 
Table 2 Continued
Major results • ECGs from 2235 healthy subjects (59% men) in thorough-QT studies analysed to characterize sex and age-dependent differences in depolarization (QRS), early repolarization (J-Tpeak), and late repolarization (Tpeak-Tend) (2014) 87 • Simulation of effects of predicted T levels (as a function of age) on ECG parameters, I second-line therapy to tamoxifen-resistant tumours that continue to utilize ER signalling to grow. 34 Unlike SERMs, SERDs do not mimic oestrogen and instead act as oestrogen antagonists, blocking the natural hormone response (Figure 1) . This is important considering the proposed mechanism for LQT and TdP risk in SERMs treatment. Fulvestrant is currently the only FDA-approved SERD used for post-menopausal breast cancer. 26 Mechanistic studies of fulvestrant show a blockade of ER dimerization and activation while promoting the ubiquitinproteasome pathway and receptor degradation. 34 Compared to AIs, fulvestrant and newer SERDs are a more direct means to regulate hormone receptor activity in the cancer microenvironment. Fulvestrant is especially powerful in treating breast cancer patients who fail to respond to other treatments, including SERMs and AIs. 34, 48 Unlike SERMs, fulvestrant is globally antagonistic to the ER and achieves therapeutic response not only by modulating receptor signalling but by abolishing the ER pathway. 34 Fulvestrant lacks the adverse agonistic effects of SERMs and currently, has no reported drug-induced LQT or TdP risks for patients with breast cancer.
•
Aromatase inhibitors
AIs potently inhibit oestrogen synthesis in the peripheral tissues of postmenopausal women such as in subcutaneous fat, the adrenal glands, or the intratumoural environment. 30 Before menopause, oestrogen is primarily synthesized in the sex organs including the ovaries, corpus luteum, and placenta. 49 However, after menopause, oestrogen synthesis occurs in peripheral tissues and is accomplished by the aromatase enzyme. AIs differ from other forms of oestrogen-deprivation therapy by targeting the aromatase enzyme directly, blocking the conversion of androstenedione, and testosterone into oestrone and oestradiol, respectively. 50 This inhibition reduces available oestrogen to bind ER on cancer cells, inhibiting cancer growth, and progression ( Figure 1) . Aromatase is a member of the cytochrome P450 (CYP) superfamily expressed predominantly in the placenta and ovarian follicles, and to a lesser extent in non-glandular tissues such as subcutaneous fat, liver, muscle, brain, cancerous, and non-cancerous breast tissue. 50 AIs are designated as an adjuvant treatment and first-line therapy for advanced breast cancer in post-menopausal women where oestrogen is primarily synthesized in the periphery. 50 In post-menopausal women, AIs are selective antagonists, unlike SERMs that can be agonists/antagonists depending on tissue environment. In pre-menopausal women, use of AIs is complicated because retrocontrol at the pituitary level associated with reduction in oestrogen circulating levels leads to an increase in gonadotropin hormone secretion reactivating ovarian production of oestrogen. 50 In these patients, AIs must be combined with luteinizing hormone-releasing hormone analogues to block both ovarian and peripheral oestrogen synthesis. 51 Currently, the FDA has approved the AIs anastrozole, exemestane, and letrozole for ER þ breast cancer in post-menopausal women only. 26 AIs reduce circulating oestrogen levels, potentially shortening the QTc interval based on studies of how oestrogen and progesterone influence repolarization. 13 AIs also cause an accumulation of androgens that do not convert to oestrogen, leading to increases in testosterone production, at least in the male population. 52 Testosterone shortens QTc, which may contribute to the lowest risk for reporting of LQT and TdP on AIs vs. SERMs (4-5-fold less) found in a recently published pharmacovigilance study using the European pharmacovigilance database. 9 Kurokawa et al. 29 showed that ablation of circulating levels of oestradiol in mice knocked out for aromatase blunted the QT prolonging effect of an I Kr blocker, E-4031. Moreover, it has been shown that high-dose anastrozole lead to QT shortening in dogs. 53 Therefore, AIs appear to be a better alternative to SERMs in women with breast cancer at risk for TdP. This issue will be more critical as endocrine therapy is combined with other therapies for the treatment of breast cancer carrying their own risk for LQT, such as CDK 4/6 inhibitors.
Recent advances: CDK 4/6 inhibitors
Recent advances in treatment of hormone-sensitive breast cancer include the development of the CDK 4/6 inhibitors. CDKs are involved in a phosphorylation pathway that drives forward the S phase of the cell cycle. CDK 4/6 inhibitors are particularly important for ER þ breast cancer because this signalling pathway is downstream of the oncogenic pathway mediated by oestrogen. 54 Targeting this pathway, in combination with other hormone therapy targets, provides a more comprehensive approach to shutting down oestrogen-signalled growth. The approved CDK 4/6 inhibitors are ribociclib, palbociclib, and abemaciclib. 26 Of the approved CDK 4/6 inhibitors, ribociclib is the only one with a warning for LQT in the FDA label. 26 In PALOMA-2, a randomized placebo-controlled trial, palbociclib associated with letrozole, administered in 444 patients (2:1 ratio) with ER þ , HER-2 negative advanced breast cancer, did not result in LQT. 55, 56 Similarly, in a Phase I study, abemaciclib was not associated with QTc modification (in 12 patients). 57 However, in a Phase I study, ribociclib increased QTc interval to more than 480 ms in at least 9% of 125 patients. QTc prolongation was dose-dependent and 33% of those who received >600 mg/day developed LQT. None of these healthy subjects developed TdP. 57, 58 Continued reporting on the frequency of LQT with CDK4/6 inhibitors, especially when used in combination with other forms of hormone therapy, will be necessary to assess the safety profile of these drugs. Current CredibleMeds website and FDA label information related to diLQT and diTdP for each of these drugs indicated in breast cancer are summarized in Table 1 .
Hormone therapies for prostate cancer
Prostate cancer accounts for every one in five male cancer diagnoses, comprising a large population of patients who receive hormonal therapy for cancer. 1 Therapeutic intervention for metastatic prostate cancer relies on eliminating circulating androgen or antagonizing its effect at the cellular level. Androgens, such as testosterone and its active metabolite 5a-dihydrotestosterone, are growth factors that stimulate prostate cancer growth and division. Androgen elimination can be achieved by surgical bilateral orchiectomy or androgen deprivation therapy (ADT) through pharmacological intervention as shown in Table 1 and Figure 2 .
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In the past, surgical castration and use of oestrogen therapy were often used but they have since been replaced by gonadotropin-releasing hormone (GnRH) agonists and other endocrine therapies. 60 The cardiovascular toxicities of oestrogen use and the psychological effects of surgical castration increased the popularity of GnRH agonists/antagonists and other forms of more effective ADT including CYP17 inhibitors and androgen receptor inhibitors. 60, 61 ADT exposes men to considerable cardiovascular risks including important electrophysiological changes. 11, 13, 14 In vitro, androgens lead to shortening of ventricular action potential duration and androgen administration in humans is associated with QTc shortening; ADT has opposite effects. influence of androgens (testosterone, 5a-dihydrotestosterone) and ADT on ventricular repolarization classified by system used and effects on the different ventricular repolarizing and depolarizing currents. Table 3) .
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CredibleMeds website and FDA label information related to diLQT and diTdP for each ADT are summarized in Table 1 .
25-27
Gonadotropin-releasing hormone agonists and antagonists
Gonadotropin-releasing hormone (GnRH) agonists and antagonists work by interfering with the GnRH receptor pathway to induce a sustained reduction of GnRH or to block GnRH receptor signalling and secretion, respectively. 95 GnRH is produced in the hypothalamus and modulates the release of luteinizing hormone (LH) and folliclestimulating hormone (FSH) from the anterior pituitary. GnRH agonists work by causing an initial surge in LH from the anterior pituitary. However, continuous stimulation through administration of the agonist causes a down-regulation of the receptor and a desensitization to endogenous or exogenous GnRH. 96 Conversely, GnRH antagonists reduce androgens by irreversibly binding the pituitary GnRH receptors, eliminating FSH, and LH secretion. The GnRH agonists include goserelin, leuprolide, triptorelin, and histrelin and GnRH antagonists include degarelix and abarelix. 26 Both the GnRH agonists and antagonists have warnings issued by the FDA for LQT and are consistently associated with increases in QTc interval by 10-20 ms (Tables 1 and 3) . [89] [90] [91] [92] [93] [94] The proposed mechanism of action for the increase in QTc interval is through testosterone interacting with cardiac ion channels as shown in Figures 2 and 3 .
13
Testosterone mainly affects ventricular repolarization by modifying I Kr , I Ks , and I CaL . 62, 63, 77 It has been shown that testosterone increases the amount of I Kr protein located in the cytoplasm and plasma membrane via an inhibition of its degradation. Testosterone was also associated with an increase in I Ks and reduction in I CaL density via non-genomic activation of c-Src, phosphatidylinositol 3-kinase/Akt and NOS3 pathway ( Table 2) . All these mechanisms contributes to shortening of ventricular repolarization.
62,63,77
Androgen receptor inhibitors
Androgen cellular effect on prostate cancer cell growth can also be blocked directly by androgen receptor inhibitors. 105 Bicalutamide, flutamide, nilutamide, enzalutamide, and apalutamide are current androgen receptor inhibitors approved by FDA for the treatment of prostate cancer. 26 Androgen receptor inhibitors act at the receptor level, blocking receptor translocation into the nucleus, DNA binding, and recruitment of co-activators for transcription. 105 Enzalutamide and apalutamide are the latest generation of more potent androgen receptor inhibitors, particularly effective in the setting of prostate cancer escaping to classical castration achieved by first generation androgen inhibitors and/or GnRH agonists. A study of enzalutamide in zebrafish showed a dose-dependent decrease in heart rate and increase in mortality, when associated with terfenadine, an I Kr blocker, further supporting the interplay between androgen deprivation and I Kr . 27 The FDA label has LQT reported with apalutamide but no formal warnings were indicated, while CredibleMeds suggests there is a possible risk of TdP with apalutamide. 25, 26 Other androgen receptor inhibitors were not classified on CredibleMeds ( Table 1) . Data on effect of total androgen blockade (GnRH anta/agonist associated with androgen receptor inhibitors) in terms of rhythmic risk are lacking and need further investigation.
CYP17 inhibitors
Abiraterone acetate is a potent inhibitor of 17a hydroxylase/c-17, 20-lyase (CYP17), a subtype of the cytochrome P450 enzymes, which is involved in androgen biosynthesis at the adrenal level. 106 Abiraterone is especially indicated when patients become 'castration-resistant' and have residual androgen synthesis despite blockade by GnRH agonists and/or antagonists. Abiraterone elicits an anti-tumour response by directly inhibiting the synthesis of androgen from cholesterol as well as indirectly blocking downstream synthesis of androgen. 107 Abiraterone also lowers the synthesis of glucocorticoids that causes a surge of adrenocorticotropic hormone (ACTH) and subsequently mineralocorticoid production upstream of the blockade, particularly aldosterone precursors such as desoxycorticosterone. 8, 107 Excess mineralocorticoid production favours hypokalaemia. 8 In efforts to control ACTH production, low-dose corticosteroids must be co-administrated with abiraterone treatment. 108 The FDA warns against mineralocorticoid excess and recommends close monitoring of patients with underlying cardiovascular disease. 26 In a trial evaluating the cardiac safety of abiraterone vs. placebo, fluid retention and hypokalaemia were significantly higher than in the control group, potentially contributing to the higher incidence of serious cardiac events in the abiraterone treated group vs. placebo (5% vs. 1%). 106 An important consideration is the concomitant use of abiraterone with other forms of ADT. To accomplish a full blockade of androgen synthesis, the FDA label requires that abiraterone be co-administered with GnRH analogues or on top of bilateral orchiectomy. 26 The combination of ADT and abiraterone has the propensity to increase arrhythmia risk due to excess mineralocorticoid synthesis, hypokalaemia and inherent risks of ADT, such as LQT, TdP, and AF. 109, 110 In fact, several studies, including a large study involving over 76 000 patients, have shown that testosterone deficiency may be associated with AF and normalization of testosterone levels reduces incidence of AF. 10, 22, 96, 111 On top of ADT effects, excess mineral corticosteroids and hypokalaemia are also known to promote AF, making abiraterone likely to be even more toxic than other ADT in this regard. 11, 110, 112 Further studies on AF frequency and severity are needed to validate the safety of ADT, particularly abiraterone in combination with ADT. In patients with metastatic hormone-sensitive prostate cancer, a meta-analysis of two trials with a median follow-up (MFU) of at least 30 months also showed that ADT plus abiraterone was associated with more cardiac disorders 109 AF incidence on abiraterone was higher in patients with more severe forms of prostate cancer; i.e. metastatic castration-resistant cases with previous chemotherapy as compared to patients with prostate cancer not previously treated with hormone therapy (incidence ranging from 1% to 5%; MFU: 12-40 months). [113] [114] [115] [116] Of note, patients with clinically significant heart diseases or uncontrolled hypertension were excluded from these trials, and pre-existing cardiovascular conditions are known risk factors of AF in patients on ADT. [117] [118] [119] Therefore, real-life incidence of AF on abiraterone plus ADT deserves further investigation.
Conclusion
LQT and TdP were more likely to be reported on SERMs as compared with other endocrine therapies used for breast cancer (AIs and SERDs). Some new anticancer drugs developed for breast cancer in combination with SERMs, such as ribociclib seem to induce and/or potentiate LQT. In prostate cancer, ADT is associated with LQT and TdP through blockade of testosterone effects on ventricular repolarization. Further investigations are needed to better understand risk of TdP associated with these liable endocrine therapies in high-risk patients such as carrier of cLQTS, cancer patients with hypokalaemia due to diarrhoea and vomiting or when treated in combination with other QT-prolonging drugs (including anti-emetics, opioids, and antibiotics). ECG monitoring and correction of concurrent liable conditions increasing the risk of TdP is advisable for these latter patients.
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